General
Preferred name
MILTEFOSINE
Synonyms
MILTEFOSINE [5mM] ()
NSC605583 ()
Hexadecyl phosphocholine ()
HEPC ()
Miltex ()
Hexadecylphosphocholine ()
NSC-605583 ()
Impavido ()
HDPC ()
NSC-758968 ()
D-18506 ()
Miltefosine-d4 ()
P&D ID
PD000933
CAS
58066-85-6
Tags
available
drug
Approved by
FDA
First approval
2014
Drug Status
investigational
approved
Drug indication
Visceral leishmaniasis
Leishmaniasis
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Miltefosine is an antiprotozoal (anthelmintic) drug that is primarily used to treat leishmaniasis. It has additional anticancer and immunomodulatory/anti-inflammatory activities . The antitumour activity of miltefosine is principally mediated through the inhibition of Akt phosphorylation , which exerts a modulatory effect on the phosphatidylinositol 3-kinase (PI3K)-Akt/PKB cellular survival pathway. (GtoPdb)
Cell lines
24
Organisms
18
Compound Sets
25
AdooQ Bioactive Compound Library
A14138
Axon Medchem Screening Library
3247
Bioprocess diversity set
Cayman Chemical Bioactives
63280
34707
ChEMBL Approved Drugs
CHEMBL125
ChEMBL Drugs
CHEMBL125
DrugBank
DB09031
DrugBank Approved Drugs
DB09031
DrugCentral
1810
DrugCentral Approved Drugs
1810
DrugMAP
DMND304
DrugMAP Approved Drugs
DMND304
DrugMatrix
Guide to Pharmacology
11355
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL125
MedChem Express Bioactive Compound Library
HY-13685
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
53EY29W7EC
NIH Mechanistic Set
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
miltefosine-hexadecylphosphocholine
TargetMol Bioactive Compound Library
T0033
The Pathogen Box
The Spectrum Collection
External IDs
39
Properties
(calculated by RDKit )
Molecular Weight
407.32
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
20
Ring Count
0
Aromatic Ring Count
0
cLogP
5.68
TPSA
58.59
Fraction CSP3
1.0
Chiral centers
1.0
Largest ring
0.0
QED
0.15
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Biological process
Resipration, oxidative phosphorylation, & mitochondrial targeting
Disease
REFERENCE COMPOUNDS
Pathway
Cytoskeletal Signaling
PI3K/Akt/mTOR signaling
Anti-infection
PI3K/Akt/mTOR
Target
PKC
Akt
HIV
Parasite
MOA
PKC inhibitor
Akt inhibitor
Biosynthetic Origin
Fatty Acid
Therapeutic Indication
Anticancer
Therapeutic Class
Antifungal Agents
Source data